Entrada Therapeutics, Inc. (TRDA) stock
Close on Nov 11, 2026Market cap $211.82MP/E –Yield –
Entrada Therapeutics, Inc. saw revenue fall 93.5% to $3.98M over the twelve months to Sep 30, 2026. Free cash flow was -$136.33M. At the latest close the market valued the company at $211.82M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $211.82M
- P/E ratio
- –
- Price to sales
- 53.26
- Price to book
- 1.07
- Dividend yield
- –
- Free cash flow yield
- -64.36%
Fundamentals
- Revenue
- $3.98M
- Net income
- -$161.39M
- EPS, diluted
- -$3.84
- Free cash flow
- -$136.33M
- Book value per share
- $4.68
- Diluted shares
- 42M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $5.25
- Open
- $5.25
- Day's range
- $4.96 – $5.49
- Volume
- 760,792
- Average volume (20 days)
- 471,855
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.96
- 52-week range
- $4.11 – $16.45
- RSI (14 days)
- 54.1
- Volatility (1 year)
- 91.2%
- Relative volume
- 1.99×
- WACC
- 9.7%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TRDA | S&P 500 | Difference | TRDA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.1% | -2.4% | −1.6 pts | ||
| 3 months | -22.7% | -1.2% | −21.6 pts | ||
| Year to date | -47.1% | +12.3% | −59.4 pts | ||
| 1 year | -29.4% | +12.4% | −41.8 pts | ||
| 3 years | -67.3% | +78.8% | −146.1 pts | -31.1% | +21.4% |
| 5 years | -83.3% | +75.2% | −158.4 pts | -30.1% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Entrada Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Results
About Entrada Therapeutics
Pharmaceutical Preparations
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a class of genetic medicines that target disease-causing mechanisms inside cells. Utilizing its proprietary Endosomal Escape Vehicle platform, the company creates intracellular therapeutics by conjugating small cyclic peptides with oligonucleotides or proteins. Its core development pipeline focuses on rare neuromuscular conditions, particularly Duchenne muscular dystrophy, through exon-skipping candidates such as ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. In addition, the company collaborates with Vertex Pharmaceuticals to advance VX-670 for myotonic dystrophy type 1 and pursues preclinical programs for inherited ocular diseases, including ENTR-801 for Usher syndrome type 2A.
Company profile, executives and historyEntrada Therapeutics stock: common questions
What is Entrada Therapeutics's stock price?
TRDA closed at $5.44 on Nov 11, 2026, up 3.62% on the day. Over the past 52 weeks it traded between $4.11 and $16.45.
What is Entrada Therapeutics's market cap?
Entrada Therapeutics was worth $211.82M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TRDA's P/E ratio?
Entrada Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.84), so it has no meaningful P/E ratio.
How much revenue does Entrada Therapeutics make?
Entrada Therapeutics reported revenue of $3.98M for the twelve months to Sep 30, 2026, down 93.5% from a year earlier.
Does Entrada Therapeutics pay a dividend?
No. Entrada Therapeutics has not paid a cash dividend over the last twelve months.
When does Entrada Therapeutics report earnings next?
Entrada Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TRDA stock performed over the past year?
Including dividends, TRDA returned -29.4% over the past year, against +12.4% for the S&P 500.
How many TRDA shares are sold short?
3M shares were sold short at the latest FINRA report, 8.46% of the float, or 6.9 days of average trading volume.
Who are Entrada Therapeutics's competitors?
Companies most similar to Entrada Therapeutics by business, industry and size include CAMP, PRAX, XBIO, IRD, COYA.
See a number that looks wrong?